Brain imaging in the study of Alzheimer's disease

NeuroImage

Volumn 61, Issue 2, 2012, Pages 505-516

  Reiman, Eric M ^a,b,c,d   Jagust, William J ^e,f  

^a BANNER ALZHEIMER S INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^d ARIZONA ALZHEIMER S CONSORTIUM   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Alzheimer's disease; Amyloid; Dementia; Diagnosis; Mild cognitive impairment; MRI; PET; Prevention

Indexed keywords

AMYLOID BETA PROTEIN; FLUORODEOXYGLUCOSE F 18;

ALZHEIMER DISEASE; BRAIN FUNCTION; CEREBROSPINAL FLUID ANALYSIS; DISEASE COURSE; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; FUNCTIONAL CONNECTIVITY MAGNETIC RESONANCE IMAGING; GENETIC PREDISPOSITION; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; LIFESTYLE MODIFICATION; MILD COGNITIVE IMPAIRMENT; NERVE CELL NETWORK; NEUROANATOMY; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; REVIEW; RISK REDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; BRAIN; DIFFUSION TENSOR IMAGING; EARLY DIAGNOSIS; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROIMAGING; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84860727971     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2011.11.075     Document Type: Review

References (180)

1. Adalsteinsson E., Sullivan E.V., Kleinhans N., Spielman D.M., Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 2000, 355:1696-1697.
2. Aizenstein H.J., Nebes R.D., Saxton J.A., Price J.C., Mathis C.A., Tsopelas N.D., Ziolko S.K., James J.A., Snitz B.E., Houck P.R., Bi W., Cohen A.D., Lopresti B.J., DeKosky S.T., Halligan E.M., Klunk W.E. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 2008, 65:1509-1517.
3. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Phelps C.H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association Workgroup. Alzheimer Dement 2011, 7:270-279.
4. Alexander G.E., Chen K., Pietrini P., Rapoport S.I., Reiman E.M. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am. J. Psychiatry 2002, 159:738-745.
5. Alexander G.E., Chen K., Reiman E.M., Caselli R.J., Lewis D., Bandy D., Prouty A. Longitudinal declines of gray matter in cognitively normal apolipoprotein E ε4 homozygotes and heterozygotes evaluated by voxel-based MRI morphometry. Neurobiol. Aging 2002, s363.
6. Baron J.C., Chetelat G., Desgranges B., Perchey G., Landeau B., de la Sayette V., Eustache F. In vivo mapping of gray matter loss with voxel-based morphometry in mild Alzheimer's disease. Neuroimage 2001, 14:298-309.
7. Bateman R.J., Aisen P.S., De Strooper B., Fox N.C., Lemere C.A., Ringman J.M., Salloway S., Sperling R.A., Windisch M., Xiong C. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res. Ther. 2011, 2:35.
8. Beckett L.A., Harvey D.J., Gamst A., Donohue M., Kornak J., Zhang H., Kuo J.H. The Alzheimer's disease neuroimaging initiative: annual change in biomarkers and clinical outcomes. Alzheimers Dement. 2010, 6:257-264.
9. Bennett D.A., Schneider J.A., Arvanitakis Z., Kelly J.F., Aggarwal N.T., Shah R.C., Wilson R.S. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006, 66:1837-1844.
10. Bokde A.L., Teipel S.J., Drzezga A., Thissen J., Bartenstein P., Dong W., Leinsinger G., Born C., Schwaiger M., Moeller H.J., Hampel H. Association between cognitive performance and cortical glucose metabolism in patients with mild Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2005, 20:352-357.
11. Bonte F.J., Ross E.D., Chehabi H.H., Devous M.D. SPECT study of regional cerebral blood flow in Alzheimer disease. J. Comput. Assist. Tomogr. 1986, 10:579-583.
12. Bonte F.J., Weiner M.F., Bigio E.H., White C.L. Brian blood flow in the dementias: SPECT with histopathologic correlation in 54 patients. Radiology 1997, 202:793-797.
13. Bookheimer S.Y., Strojwas M.H., Cohen M.S., Saunders A.M., Pericak-Vance M.A., Mazziotta J.C., Small G.W. Patterns of brain activation in people at risk for Alzheimer's disease. N. Engl. J. Med. 2000, 343:450-456.
14. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl) 1991, 82:239-259.
15. Brickman A.M., Honig L.S., Scarmeas N., Tatarina O., Sanders L., Albert M.S., Brandt J., Blacker D., Stern Y. Measuring cerebral atrophy and white matter hyperintensity burden to predict the rate of cognitive decline in Alzheimer disease. Arch. Neurol. 2008, 65:1202-1208.
16. Buckner R.L., Snyder A.Z., Shannon B.J., LaRossa G., Sachs R., Fotenos A.F., Sheline Y.I., Klunk W.E., Mathis C.A., Morris J.C., Mintun M.A. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J. Neurosci. 2005, 25:7709-7717.
17. Buckner R.L., Sepulcre J., Talukdar T., Krienen F.M., Liu H., Hedden T., Andrews-Hanna J.R., Sperling R.A., Johnson K.A. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J. Neurosci. 2009, 29:1860-1873.
18. Cagnin A., Brooks D.J., Kennedy A.M., Gunn R.N., Myers R., Turkheimer F.E., Jones T., Banati R.B. In-vivo measurement of activated microglia in dementia. Lancet 2001, 358:461-467.
19. Celone K.A., Calhoun V.D., Dickerson B.C., Atri A., Chua E.F., Miller S.L., DePeau K., Rentz D.M., Selkoe D.J., Blacker D., Albert M.S., Sperling R.A. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J. Neurosci. 2006, 26:10222-10231.
20. Chen K., Reiman E.M., Alexander G.E., Caselli R.J., Gerkin R., Bandy D., Domb A., Osborne D., Fox N., Crum W.R., Saunders A.M., Hardy J. Correlations between apolipoprotein E ε4 gene dose and whole brain atrophy rates. Am. J. Psychiatry 2007, 164:916-921.
21. Chen K., Langbaum J.B.S., Fleisher A.S., Ayutyanont N., Reschke C., Lee W., Liu X., Bandy D., Alexander G.E., Thompson P.M., Foster N.L., Harvey D.J., de Leon M.J., Koeppe R.A., Jagust W.J., Weiner M.W., Reiman E.M., the Alzheimer's Disease Neuroimaging Initiative Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's disease neuroimaging initiative. Neuroimage 2010, 51:654-664.
22. Chen K., Ayutyanont N., Langbaum J.B.S., Fleisher A.S., Reschke C., Lee W., Liu X., Bandy D., Alexander G.E., Thompson P.M., Shaw L., Trojanowki J.Q., Jack C.R., Landau S.M., Foster N.L., Harvey D.J., Weiner M.W., Koeppe R.A., Jagust W.J., Reiman E.M., Alzheimer's Disease Neuroimaging Initiative Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage 2011, 56:52-60.
23. Chetelat G., Desgranges B., De La Sayette V., Viader F., Eustache F., Baron J.C. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology 2003, 60:1374-1377.
24. Chetelat G., Desgranges B., de la Sayette V., Viader F., Berkouk K., Landeau B., Lalevee C., Le D.F., Dupuy B., Hannequin D., Baron J.C., Eustache F. Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain 2003, 126:1955-1967.
25. Chetelat G., Villemagne V.L., Bourgeat P., Pike K.E., Jones G., Ames D., Ellis K.A., Szoeke C., Martins R.N., O'Keefe G.J., Salvado O., Masters C.L., Rowe C.C. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann. Neurol. 2010, 67:317-324.
26. Chételat G., Eustache F., Viader F., de la Sayette V., Pélerin A., Mézenge F., Hannequin D., Dupuy B., Baron J.C., Desgranges B. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 2005, 11:14-25.
27. Chételat G., Landeau B., Eustache F., Mézenge F., Viader F., de la Sayette V., Desgranges B., Baron J.C. Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI: a longitudinal MRI study. Neuroimage 2005, 27:934-946.
28. Choi S.R., Golding G., Zhuang Z., Zhang W., Lim N., Hefti F., Benedum T.E., Kilbourn M.R., Skovronsky D., Kung H.F. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J. Nucl. Med. 2009, 50:1887-1894.
29. Choo I.H., Lee D.Y., Youn J.C., Jhoo J.H., Kim K.W., Lee D.S., Lee J.S., Woo J.I. Topographic patterns of brain functional impairment progression according to clinical severity staging in 116 Alzheimer disease patients: FDG-PET study. Alzheimer Dis. Assoc. Disord. 2007, 21:77-84.
30. Clark C.M., Schneider J.A., Bedell B.J., Beach T.G., Bilker W.B., Mintun M.A., Pontecorvo M.J., Hefti F., Carpenter A.P., Flitter M.L., Krautkramer M.J., Kung H.F., Coleman R.E., Doraiswamy P.M., Fleisher A.S., Sabbagh M.N., Sadowsky C.H., Reiman P.E., Zehntner S.P., Skovronsky D.M. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011, 305:275-283.
31. de Leon M.J., George A.E., Stylopoulos L.A., Smith G., Miller D.C. Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet 1989, 2:672-673.
32. De Santi S., de Leon M.J., Rusinek H., Convit A., Tarshish C.Y., Roche A., Tsui W.H., Kandil E., Boppana M., Daisley K., Wang G.J., Schlyer D., Fowler J. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol. Aging 2001, 22:529-539.
33. DeKosky S.T., Shih W.J., Schmitt F.A., Coupal J., Kirkpatrick C. Assessing utility of single photon emission computed tomography (SPECT) scan in Alzheimer disease: correlation with cognitive severity. Alzheimer Dis. Assoc. Disord. 1990, 4:14-23.
34. den Heijer T., Oudkerk M., Launer L.J., Van Duijn C.M., Hofman A., Breteler M.M. Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes. Neurology 2002, 59:746-748.
35. Dickerson B.C., Goncharova I., Sullivan M.P., Forchetti C., Wilson R.S., Bennett D.A., Beckett L.A., Toledo-Morrell L. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol. Aging 2001, 22:747-754.
36. Dickerson B.C., Salat D.H., Bates J.F., Atiya M., Killiany R.J., Greve D.N., Dale A.M., Stern C.E., Blacker D., Albert M.S., Sperling R.A. Medial temporal lobe function and structure in mild cognitive impairment. Ann. Neurol. 2004, 56:27-35.
37. Dickerson B.C., Bakkour A., Salat D.H., Feczko E., Pacheco J., Greve D.N., Grodstein F., Wright C.I., Blacker D., Rosas H.D., Sperling R.A., Atri A., Growdon J.H., Hyman B.T., Morris J.C., Fischl B., Buckner R.L. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb. Cortex 2009, 19:497-510.
38. Doraiswamy P.M., Farmer M., Holub R., Johnson K., Reiman E.M., Sadowsky C., Safirstein B., Spicer K., Carpenter A., Clark C.M., Joshi A., Veeraraj C., Pontecorvo M.J., Skovronsky D. Relationship between regional amyloid levels and cognitive performance in healthy controls, MCI subjects, and patients with AD: phase II results from a florpiramine F18 PET imaging study. Alzheimers Dement. 2009, 5:P77.
39. Drzezga A., Grimmer T., Riemenschneider M., Lautenschlager N., Siebner H., Alexopoulus P., Minoshima S., Schwaiger M., Kurz A. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J. Nucl. Med. 2005, 46:1625-1632.
40. Drzezga A., Riemenschneider M., Strassner B., Grimmer T., Peller M., Knoll A., Wagenpfeil S., Minoshima S., Schwaiger M., Kurz A. Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology 2005, 64:102-107.
41. Du A.T., Schuff N., Kramer J.H., Rosen H.J., Gorno-Tempini M.L., Rankin K., Miller B.L., Weiner M.W. Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia. Brain 2007, 130:1159-1166.
42. Dubois B., Feldman H.H., Jacova C., DeKosky S.T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P.J., Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6:734-746.
43. Dubois B., Feldman H.H., Jacova C., Cummings J.L., DeKosky S.T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N.C., Galasko D., Gauthier S., Hampel H., Jicha G.A., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Sarazin M., de Souza L.C., Stern Y., Visser P.J., Scheltens P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010, 9:1118-1127.
44. Edison P., Archer H.A., Gerhard A., Hinz R., Pavese N., Turkheimer F.E., Hammers A., Tai Y.F., Fox N., Kennedy A., Rossor M., Brooks D.J. Microglia, amyloid, and cognition in Alzheimer's disease: an [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol. Dis. 2008, 32:412-419.
45. Espeseth T., Westlye L.T., Fjell A.M., Walhovd K.B., Rootwelt H., Reinvang I. Accelerated age-related cortical thinning in healthy carriers of apolipoprotein E epsilon 4. Neurobiol. Aging 2008, 29:329-340.
46. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann. Neurol. 2006, 59:512-519.
47. Fellgiebel A., Dellani P.R., Greverus D., Scheurich A., Stoeter P., Muller M.J. Predicting conversion to dementia in mild cognitive impairment by volumetric and diffusivity measurements of the hippocampus. Psychiatry Res. 2006, 146:283-287.
48. Fodero-Tavoletti M.T., Rowe C.C., McLean C.A., Leone L., Li Q.X., Masters C.L., Cappai R., Villemagne V.L. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J. Nucl. Med. 2009, 50:198-204.
49. Forsberg A., Engler H., Almkvist O., Blomquist G., Hagman G., Wall A., Ringheim A., Långstrom B., Nordberg A. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 2008, 29:1456-1465.
50. Foster N.L., Chase T.N., Fedio P., Patronas N.J., Brooks R.A., Di Chiro G. Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology 1983, 33:961-965.
51. Foster N.L., Heidebrink J.L., Clark C.M., Jagust W.J., Arnold S.E., Barbas N.R., DeCarli C.S., Turner R.S., Koeppe R.A., Higdon R., Minoshima S. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007, 130:2616-2635.
52. Fox N.C., Cousens S., Scahill R., Harvey R.J., Rossor M.N. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch. Neurol. 2000, 57:339-344.
53. Goos J.D., Henneman W.J., Sluimer J.D., Vrenken H., Sluimer I.C., Barkhof F., Blankenstein M.A., Scheltens P.H., van der Flier W.M. Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. Neurology 2010, 74:1954-1960.
54. Gosche K.M., Mortimer J.A., Smith C.D., Markesbery W.R., Snowdon D.A. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 2002, 58:1476-1482.
55. Greicius M.D., Srivastava G., Reiss A.L., Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:4637-4642.
56. Grimmer T., Henriksen G., Wester H., Förstl H., Klunk W.E., Mathis C.A., Kurz A., Drzezga A. Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol. Aging 2009, 30:1902-1909.
57. Haag M.D.M., Hofman A., Koudstaal P.J., Stricker B.H.C., Breteler M.M.B. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry 2009, 80:13-17.
58. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
59. Haxby J.V., Duara R., Grady C.L., Cutler N.R., Rapoport S.I. Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease. J. Cereb. Blood Flow Metab. 1985, 5:193-200.
60. Haxby J.V., Grady C.L., Koss E., Horwitz B., Heston L., Schapiro M., Friedland R.P., Rapoport S.I. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch. Neurol. 1990, 47:753-760.
61. Hedden T., Van Dijk K.R., Becker J.A., Mehta A., Sperling R.A., Johnson K.A., Buckner R.L. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J. Neurosci. 2009, 29:12686-12694.
62. Herholz K., Nordberg A., Salmon E., Perani D., Kessler J., Mielke R., Halber M., Jelic V., Almkvist O., Collette F., Alberoni M., Kennedy A., Hasselbalch S., Fazio F., Heiss W.D. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 1999, 10:494-504.
63. Herholz K., Salmon E., Perani D., Baron J.C., Holthoff V., Frolich L., Schonknecht P., Ito K., Mielke R., Kalbe E., Zundorf G., Delbeuck X., Pelati O., Anchisi D., Fazio F., Kerrouche N., Desgranges B., Eustache F., Beuthien-Baumann B., Menzel C., Schroder J., Kato T., Arahata Y., Henze M., Heiss W.D. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002, 17:302-316.
64. Hoffman J.M., Welsh-Bohmer K.A., Hanson M., Crain B., Hulette C., Earl N., Coleman R.E. FDG PET imaging in patients with pathologically verified dementia. J. Nucl. Med. 2000, 41:1920-1928.
65. Holman B.L., Johnson K.A., Gerada B., Carvalho P.A., Satlin A. The scintigraphic appearance of Alzheimer's disease: a prospective study using technetium-99m-HMPAO SPECT. J. Nucl. Med. 1992, 33:181-185.
66. Ikonomovic M.D., Klunk W.E., Abrahamson E.E., Mathis C.A., Price J.C., Tsopelas N.D., Lopresti B.J., Ziolko S., Bi W., Paljug W.R., Debnath M.L., Hope C.E., Isanski B.A., Hamilton R.L., DeKosky S.T. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008, 131:1630-1645.
67. Jack C.R., Petersen R.C., Xu Y.C., O'Brien P.C., Smith G.E., Ivnik R.J., Boeve B.F., Waring S.C., Tangalos E. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999, 52:1397-1403.
68. Jack C.R., Shiung M.M., Gunter J.L., O'Brien P.C., Weigand S.D., Knopman D.S., Boeve B.F., Ivnik R.J., Smith G.E., Cha R.H., Tangalos E.G., Petersen R.C. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004, 62:591-600.
69. Jack C.R., Shiung M.M., Weigand S.D., O'Brien P.C., Gunter J.L., Boeve B.F., Knopman D.S., Smith G.E., Ivnik R.J., Tangalos E.G., Petersen R.C. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology 2005, 65:1227-1231.
70. Jack C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., Knopman D.S., Boeve B.F., Klunk W.E., Mathis C.A., Petersen R.C. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131:665-680.
71. Jack C.R., Lowe V.J., Weigand S.D., Wiste H.J., Senjem M.L., Knopman D.S., Shiung M.M., Gunter J.L., Boeve B.F., Kemp B.J., Weiner M., Petersen R.C., the Alzheimer's Disease Neuroimaging Initiative Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009, 132:1355-1365.
72. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
73. Jagust W.J., Mormino E.C. Lifespan brain activity, beta-amyloid, and Alzheimer's disease. Trends Cogn. Sci. 2011, 15:520-526.
74. Jagust W.J., Friedland R.P., Budinger T.F., Koss E., Ober B. Longitudinal studies of regional cerebral metabolism in Alzheimer's disease. Neurology 1988, 38:909-912.
75. Jagust W., Thisted R., Devous M.D., Van Heertum R., Mayberg H., Jobst K., Smith A.D., Borys N. SPECT perfusion imaging in the diagnosis of Alzheimer's disease: a clinical-pathologic study. Neurology 2001, 56:950-956.
76. Jak A.J., Houston W.S., Nagel B.J., Corey-Bloom J., Bondi M.W. Differential cross-sectional and longitudinal impact of APOE genotype on hippocampal volumes in nondemented older adults. Dement. Geriatr. Cogn. Disord. 2007, 23:382-389.
77. Johnson K.A., Jones K., Holman B.L., Becker J.A., Spiers P.A., Satlin A., Albert M.S. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1998, 50:1563-1571.
78. Jureus A., Swahn B.M., Sandell J., Jeppsson F., Johnson A.E., Johnstrom P., Neelissen J.A., Sunnemark D., Farde L., Svensson S.P. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J. Neurochem. 2010, 114:784-794.
79. Kadir A., Nordberg A. Target-specific PET probes for neurodegenerative disorders related to dementia. J. Nucl. Med. 2010, 51:1418-1430.
80. Kantarci K., Petersen R.C., Boeve B.F., Knopman D.S., Tang-Wai D.F., O'Brien P.C., Weigand S.D., Edland S.D., Smith G.E., Ivnik R.J., Ferman T.J., Tangalos E.G., Jack C.R. 1H MR spectroscopy in common dementias. Neurology 2004, 63:1393-1398.
81. Kaye J.A., Swihart T., Howieson D., Dame A., Moore M.M., Karnos T., Camicioli R., Ball M., Oken B., Sexton G. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology 1997, 48:1297-1304.
82. Kemppainen N.M., Aalto S., Wilson I.A., Nagren K., Helin S., Bruck A., Oikonen V., Kailajarvi M., Scheinin M., Viitanen M., Parkkola R., Rinne J.O. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007, 68:1603-1606.
83. Kennedy A.M., Frackowiak R.S., Newman S.K., Bloomfield P.M., Seaward J., Roques P., Lewington G., Cunningham V.J., Rossor M.N. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci. Lett. 1995, 186:17-20.
84. Kimberly W.T., Gilson A., Rost N.S., Rosand J., Viswanathan A., Smith E.E., Greenberg S.M. Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. Neurology 2009, 72:1230-1235.
85. Kiuchi K., Morikawa M., Taoka T., Nagashima T., Yamauchi T., Makinodan M., Norimoto K., Hashimoto K., Kosaka J., Inoue Y., Inoue M., Kichikawa K., Kishimoto T. Abnormalities of the uncinate fasciculus and posterior cingulate fasciculus in mild cognitive impairment and early Alzheimer's disease: a diffusion tensor tractography study. Brain Res. 2009, 1287:184-191.
86. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann. Neurol. 2004, 55:306-319.
87. Klunk W.E., Mathis C.A., Price J.C., Lopresti B.J., DeKosky S.T. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006, 129:2805-2807.
88. Klunk W.E., Price J.C., Mathis C.A., Tsopelas N.D., Lopresti B.J., Ziolko S.K., Bi W., Hoge J.A., Cohen A.D., Ikonomovic M.D., Saxton J.A., Snitz B.E., Pollen D.A., Moonis M., Lippa C.F., Swearer J.M., Johnson K.A., Rentz D.M., Fischman A.J., Aizenstein H.J., DeKosky S.T. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J. Neurosci. 2007, 27:6174-6184.
89. Knopman D.S., DeKosky S.T., Cummings J.L., Chui H., Corey-Bloom J., Relkin N., Small G.W., Miller B., Stevens J.C. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1143-1153.
90. Kuhl D.E., Koeppe R.A., Minoshima S., Snyder S.E., Ficaro E.P., Foster N.L., Frey K.A., Kilbourn M.R. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology 1999, 52:691-699.
91. Landau S.M., Harvey D., Madison C.M., Reiman E.M., Foster N.L., Aisen P.S., Petersen R.C., Shaw L.M., Trojanowski J.Q., Jack C.R., Weiner M.W., Jagust W.J. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010, 75:230-238.
92. Landau S.M., Harvey D., Madison C.M., Koeppe R.A., Reiman E.M., Foster N.L., Weiner M.W., Jagust W.J. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging 2011, 32:1207-1218.
93. Langbaum J.B.S., Chen K., Lee W., Reschke C., Bandy D., Fleisher A.S., Alexander G.E., Foster N.L., Weiner M.W., Koeppe R.A., Jagust W.J., Reiman E.M. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage 2009, 45:1107-1116.
94. Langbaum J.B., Chen K., Caselli R.J., Lee W., Reschke C., Bandy D., Alexander G.E., Burns C.M., Kaszniak A.W., Reeder S.A., Corneveaux J.J., Allen A.N., Pruzin J., Huentelman M.J., Fleisher A.S., Reiman E.M. Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele. Arch. Neurol. 2010, 67:462-468.
95. Lautenschlager N.T., Cox K.L., Flicker L., Foster J.K., van Bockxmeer F.M., Xiao J., Greenop K.R., Almeida O.P. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. JAMA 2008, 300:1027-1037.
96. Li Y., Rinne J.O., Mosconi L., Pirraglia E., Rusinek H., DeSanti S., Kemppainen N., Nagren K., Kim B.C., Tsui W., de Leon M.J. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:2169-2181.
97. Lustig C., Snyder A.Z., Bhakta M., O'Brien K.C., McAvoy M., Raichle M.E., Morris J.C., Buckner R.L. Functional deactivations: change with age and dementia of the Alzheimer type. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:14504-14509.
98. Mathis C.A., Bacskai B.J., Kajdasz S.T., McLellan M.E., Frosch M.P., Hyman B.T., Holt D.P., Wang Y., Huang G.F., Debnath M.L., Klunk W.E. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg. Med. Chem. Lett. 2002, 12:295-298.
99. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Thies W., Weintraub S., Phelps C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association Workgroup. Alzheimers Dement 2011, 7:263-269.
100. Medina D., Detoledo-Morrell L., Urresta F., Gabrieli J.D., Moseley M., Fleischman D., Bennett D.A., Leurgans S., Turner D.A., Stebbins G.T. White matter changes in mild cognitive impairment and AD: a diffusion tensor imaging study. Neurobiol. Aging 2006, 27:663-672.
101. Miller B.L., Cummings J.L., Villaneuva-Meyer J., Boone K., Mehringer C.M., Lesser I.M., Mena I. Frontal lobe degeneration: clinical, neuropsychological, and SPECT characteristics. Neurology 1991, 41:1374-1382.
102. Minoshima S., Giordani B., Berent S., Frey K.A., Foster N.L., Kuhl D.E. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann. Neurol. 1997, 42:85-94.
103. Mintun M.A., Larossa G.N., Sheline Y.I., Dence C.S., Lee S.Y., Mach R.H., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452.
104. Mormino E.C., Kluth J.T., Madison C.M., Rabinovici G.D., Baker S.L., Miller B.L., Koeppe R.A., Mathis C.A., Weiner M.W., Jagust W.J. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009, 132:1310-1323.
105. Mormino E.C., Smiljic A., Hayenga A.O., Onami H., Greicius M.D., Rabinovici G.D., Janabi M., Baker S.L., Yen V., Madison C.M., Miller B.L., Jagust W.J. Relationships between beta-amyloid and functional connectivity in different components of the default mode network in aging. Cereb. Cortex 2011, 21:2399-2407.
106. Morris J.C., Roe C.M., Grant E.A., Head D., Storandt M., Goate A.M., Fagan A.M., Holtzman D.M., Mintun M.A. Pittsburgh Compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch. Neurol. 2009, 66:1469-1475.
107. Morris J.C., Roe C.M., Xiong C., Fagan A.M., Goate A.M., Holtzman D.M., Mintun M.A. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann. Neurol. 2010, 67:122-131.
108. Mosconi L., Perani D., Sorbi S., Herholz K., Nacmias B., Holthoff V., Salmon E., Baron J.C., De Cristofaro M.T., Padovani A., Borroni B., Franceschi M., Bracco L., Pupi A. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004, 63:2332-2340.
109. Mosconi L., Pupi A., De Cristofaro M.T., Fayyaz M., Sorbi S., Herholz K. Functional interactions of the entorhinal cortex: an 18F-FDG PET study on normal aging and Alzheimer's disease. J. Nucl. Med. 2004, 45:382-392.
110. Mosconi L., Tsui W.H., De Santi S., Li J., Rusinek H., Convit A., Li Y., Boppana M., de Leon M.J. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 2005, 64:1860-1867.
111. Mosconi L., Sorbi S., de Leon M.J., Li Y., Nacmias B., Myoung P.S., Tsui W., Ginestroni A., Bessi V., Fayyazz M., Caffarra P., Pupi A. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J. Nucl. Med. 2006, 47:1778-1786.
112. Mosconi L., De S.S., Brys M., Tsui W.H., Pirraglia E., Glodzik-Sobanska L., Rich K.E., Switalski R., Mehta P.D., Pratico D., Zinkowski R., Blennow K., de Leon M.J. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol. Psychiatry 2008, 63:609-618.
113. Mosconi L., Mistur R., Switalski R., Tsui W.H., Glodzik L., Li Y., Pirraglia E., De S.S., Reisberg B., Wisniewski T., de Leon M.J. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:811-822.
114. Mueller S.G., Weiner M.W., Thal L.J., Petersen R.C., Jack C.R., Jagust W., Trojanowski J.Q., Toga A.W., Beckett L. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 2005, 1:55-66.
115. Nagren K., Halldin C., Rinne J.O. Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2010, 37:1575-1593.
116. Nelissen N., Vandenbulcke M., Fannes K., Verbruggen A., Peeters R., Dupont P., Van Laere K., Bormans G., Vandenberghe R. Abeta amyloid deposition in the language system and how the brain responds. Brain 2007, 130:2055-2069.
117. Nelissen N., Van L.K., Thurfjell L., Owenius R., Vandenbulcke M., Koole M., Bormans G., Brooks D.J., Vandenberghe R. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J. Nucl. Med. 2009, 50:1251-1259.
118. Nordberg A., Lundqvist H., Hartvig P., Andersson J., Johansson M., Hellstrom-Lindahi E., Langstrom B. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: effect of tacrine treatment. Dement. Geriatr. Cogn. Disord. 1997, 8:78-84.
119. Nordberg A., Rinne J.O., Kadir A., Langstrom B. The use of PET in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:78-87.
120. O'Brien J.L., O'Keefe K.M., LaViolette P.S., DeLuca A.N., Blacker D., Dickerson B.C., Sperling R.A. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology 2010, 74:1969-1976.
121. Okello A., Edison P., Archer H.A., Turkheimer F.E., Kennedy J., Bullock R., Walker Z., Kennedy A., Fox N., Rossor M., Brooks D.J. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009, 72:56-62.
122. Okello A., Koivunen J., Edison P., Archer H.A., Turkheimer F.E., Nagren K., Bullock R., Walker Z., Kennedy A., Fox N.C., Rossor M.N., Rinne J.O., Brooks D.J. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 2009, 73:754-760.
123. Palop J.J., Chin J., Roberson E.D., Wang J., Thwin M.T., Bien-Ly N., Yoo J., Ho K.O., Yu G.Q., Kreitzer A., Finkbeiner S., Noebels J.L., Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
124. Pappata S., Salvatore E., Postiglione A. In vivo imaging of neurotransmission and brain receptors in dementia. J. Neuroimaging 2008, 18:111-124.
125. Peila R., White L.R., Masaki K., Petrovitch H., Launer L.J. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke 2006, 37:1165-1170.
126. Petersen R.C., Stevens J.C., Ganguli M., Tangalos E.G., Cummings J.L., DeKosky S.T. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56:1133-1142. [Comment In: Neurology. 2001 May 8;56(9):1131-2 UI: 21241015].
127. Petrella J.R., Sheldon F.C., Prince S.E., Calhoun V.D., Doraiswamy P.M. Default mode network connectivity in stable vs progressive mild cognitive impairment. Neurology 2011, 76:511-517.
128. Pike K.E., Savage G., Villemagne V.L., Ng S., Moss S.A., Maruff P., Mathis C.A., Klunk W.E., Masters C.L., Rowe C.C. β-Amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130:2837-2844.
129. Quiroz Y.T., Budson A.E., Celone K., Ruiz A., Newmark R., Castrillon G., Lopera F., Stern C.E. Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Ann. Neurol. 2010, 68:865-875.
130. Rabinovici G.D., Jagust W.J., Furst A.J., Ogar J.M., Racine C.A., Mormino E.C., O'Neil J.P., Lal R.A., Dronkers N.F., Miller B.L., Gorno-Tempini M.L. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann. Neurol. 2008, 64:388-401.
131. Raichle M.E., MacLeod A.M., Snyder A.Z., Powers W.J., Gusnard D.A., Shulman G.L. A default mode of brain function. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:676-682.
132. Reiman E.M., Langbaum J.B.S. Brain imaging in the evaluation of putative Alzheimer's disease slowing, risk-reducing and prevention therapies. Imaging the Aging Brain 2009, 319-350. Oxford University Press, New York. W.J. Jagust, M. D'Esposito (Eds.).
133. Reiman E.M., Caselli R.J., Yun L.S., Chen K., Bandy D., Minoshima S., Thibodeau S.N., Osborne D. Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. N. Engl. J. Med. 1996, 334:752-758.
134. Reiman E.M., Caselli R.J., Chen K., Alexander G.E., Bandy D., Frost J. Declining brain activity in cognitively normal apolipoprotein E ε4 heterozygotes: a foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:3334-3339.
135. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:284-289.
136. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Hardy J. Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8299-8302.
137. Reiman E.M., Chen K., Liu X., Bandy D., Yu M., Lee W., Ayutyanont N., Keppler J., Reeder S.A., Langbaum J.B.S., Alexander G.E., Klunk W.E., Mathis C.A., Price J.C., Aizenstein H.J., DeKosky S.T., Caselli R.J. Fibrillar amyloid-β burden in cognitively normal people at three levels of genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:6820-6825.
138. Reiman E.M., Langbaum J.B.S., Tariot P.N. Alzheimer's Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark. Med. 2010, 4:3-14.
139. Reiman E.M., Langbaum J.B.S., Fleisher A.S., Caselli R.J., Chen K., Ayutyanont N., Quiroz Y.T., Kosik K.S., Lopera F., Tariot P.N. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J. Alzheimers Dis. 2011, 25:293-301.
140. Rentz D.M., Locascio J.J., Becker J.A., Moran E.K., Eng E., Buckner R.L., Sperling R.A., Johnson K.A. Cognition, reserve, and amyloid deposition in normal aging. Ann. Neurol. 2010, 67:353-364.
141. Resnick S.M., Sojkova J., Zhou Y., An Y., Ye W., Holt D.P., Dannals R.F., Mathis C.A., Klunk W.E., Ferrucci L., Kraut M.A., Wong D.F. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010, 74:807-815.
142. Rimajova M., Lenzo N.P., Wu J.S., Bates K.A., Campbell A., Dhaliwal S.S., McCarthy M., Rodrigues M., Paton A., Rowe C., Foster J.K., Martins R.N. Fluoro-2-deoxy-D-glucose (FDG)-PET in APOE epsilon4 carriers in the Australian population. J. Alzheimers Dis. 2008, 13:137-146.
143. Rinne J.O., Brooks D.J., Rossor M.N., Fox N.C., Bullock R., Klunk W.E., Mathis C.A., Blennow K., Barakos J., Okello A.A., de Liano S.R.M., Liu E., Koller M., Gregg K.M., Schenk D., Black R., Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010, 9:363-372.
144. Rogalski E., Cobia D., Harrison T.M., Wieneke C., Thompson C.K., Weintraub S., Mesulam M.M. Anatomy of language impairments in primary progressive aphasia. J. Neurosci. 2011, 31:3344-3350.
145. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W.E., Mathis C.A., Price J.C., Masters C.L., Villemagne V.L. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-1725.
146. Rowe C.C., Ackerman U., Browne W., Mulligan R., Pike K.L., O'Keefe G., Tochon-Danguy H., Chan G., Berlangieri S.U., Jones G., Ckinson-Rowe K.L., Kung H.P., Zhang W., Kung M.P., Skovronsky D., Dyrks T., Holl G., Krause S., Friebe M., Lehman L., Lindemann S., Dinkelborg L.M., Masters C.L., Villemagne V.L. Imaging of amyloid beta in Alzheimer's disease with (18)F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008, 7:129-135.
147. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., Fripp J., Tochon-Danguy H., Morandeau L., O'Keefe G., Price R., Raniga P., Robins P., Acosta O., Lenzo N., Szoeke C., Salvado O., Head R., Martins R., Masters C.L., Ames D., Villemagne V.L. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging 2010, 31:1275-1283.
148. Scarmeas N., Luchsinger J.A., Schupf N., Brickman A.M., Cosentino S., Tang M.X., Stern Y. Physical activity, diet, and risk of Alzheimer disease. JAMA 2009, 302:627-637.
149. Scholl M., Almkvist O., Axelman K., Stefanova E., Wall A., Westman E., Langstrom B., Lannfelt L., Graff C., Nordberg A. Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation. Neurobiol. Aging 2011, 32:1388-1399.
150. Schuff N., Amend D., Ezekiel F., Steinman S.K., Tanabe J., Norman D., Jagust W., Kramer J.H., Mastrianni J.A., Fein G., Weiner M.W. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 1997, 49:1513-1521.
151. Seeley W.W., Crawford R.K., Zhou J., Miller B.L., Greicius M.D. Neurodegenerative diseases target large-scale human brain networks. Neuron 2009, 62:42-52.
152. Sexton C.E., Kalu U.G., Filippini N., Mackay C.E., Ebmeier K.P. A meta-analysis of diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 2011, 32:e5-18.
153. Shaw P., Lerch J.P., Pruessner J.C., Taylor K.N., Rose A.B., Greenstein D., Clasen L., Evans A., Rapoport J.L., Giedd J.N. Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study. Lancet Neurol. 2007, 6:494-500.
154. Sheline Y.I., Raichle M.E., Snyder A.Z., Morris J.C., Head D., Wang S., Mintun M.A. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol. Psychiatry 2010, 67:584-587.
155. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., Read S., Satyamurthy N., Petric A., Huang S.C., Barrio J.R. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 2002, 10:24-35.
156. Silverman D.H., Small G.W., Chang C.Y., Lu C.S., Kung De Aburto M.A., Chen W., Czernin J., Rapoport S.I., Pietrini P., Alexander G.E., Schapiro M.B., Jagust W.J., Hoffman J.M., Welsh-Bohmer K.A., Alavi A., Clark C.M., Salmon E., de Leon M.J., Mielke R., Cummings J.L., Kowell A.P., Gambhir S.S., Hoh C.K., Phelps M.E. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001, 286:2120-2127.
157. Small G.W., Mazziotta J.C., Collins M.T., Baxter L.R., Phelps M.E., Mandelkern M.A., Kaplan A., La Rue A., Adamson C.F., Chang L. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995, 273:942-947.
158. Small G.W., Ercoli L.M., Silverman D.H., Huang S.C., Komo S., Bookheimer S.Y., Lavretsky H., Miller K., Siddarth P., Rasgon N.L., Mazziotta J.C., Saxena S., Wu H.M., Mega M.S., Cummings J.L., Saunders A.M., Pericak-Vance M.A., Roses A.D., Barrio J.R., Phelps M.E. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:6037-6042.
159. Small G.W., Siddarth P., Burggren A.C., Kepe V., Ercoli L.M., Miller K.J., Lavretsky H., Thompson P.M., Cole G.M., Huang S.C., Phelps M.E., Bookheimer S.Y., Barrio J.R. Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Arch. Gen. Psychiatry 2009, 66:81-87.
160. Sojkova J., Driscoll I., Iacono D., Zhou Y., Codispoti K.E., Kraut M.A., Ferrucci L., Pletnikova O., Mathis C.A., Klunk W.E., O'Brien R.J., Wong D.F., Troncoso J.C., Resnick S.M. In vivo fibrillar -amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults. Arch. Neurol. 2011, 68:232-240.
161. Sperling R.A., LaViolette P.S., O'Keefe K., O'Brien J., Rentz D.M., Pihlajamaki M., Marshall G., Hyman B.T., Selkoe D.J., Hedden T., Buckner R.L., Becker J.A., Johnson K.A. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009, 63:178-188.
162. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement. 2011, 7:280-292.
163. Storandt M., Mintun M.A., Head D., Morris J.C. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch. Neurol. 2009, 66:1476-1481.
164. Szekely C.A., Green R.C., Breitner J.C.S., Ostbye T., Beiser A.S., Corrada M.M., Dodge H.H., Ganguli M., Kawas C.H., Kuller L.H., Psaty B.M., Resnick S.M., Wolf P.A., Zonderman A.B., Welsh-Bohmer K.A., Zandi P.P. No advantage of Aβ42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 2008, 70:2291-2298.
165. Tolboom N., Yaqub M., van der Flier W.M., Boellaard R., Luurtsema G., Windhorst A.D., Barkhof F., Scheltens P., Lammertsma A.A., van Berckel B.N.M. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. J. Nucl. Med. 2009, 50:191-197.
166. Tomlinson B.E., Blessed G., Roth M. Observations on the brains of non-demented old people. J. Neurol. Sci. 1968, 7:331-336.
167. Vaishnavi S.N., Vlassenko A.G., Rundle M.M., Snyder A.Z., Mintun M.A., Raichle M.E. Regional aerobic glycolysis in the human brain. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:17757-17762.
168. Valenzuela M.J., Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 2001, 56:592-598.
169. Vandenberghe R., Van L.K., Ivanoiu A., Salmon E., Bastin C., Triau E., Hasselbalch S., Law I., Andersen A., Korner A., Minthon L., Garraux G., Nelissen N., Bormans G., Buckley C., Owenius R., Thurfjell L., Farrar G., Brooks D.J. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann. Neurol. 2010, 68:319-329.
170. Villemagne V.L., Ataka S., Mizuno T., Brooks W.S., Wada Y., Kondo M., Jones G., Watanabe Y., Mulligan R., Nakagawa M., Miki T., Shimada H., O'Keefe G.J., Masters C.L., Mori H., Rowe C.C. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch. Neurol. 2009, 66:1537-1544.
171. Villemagne V.L., Pike K.E., Chetelat G., Ellis K.A., Mulligan R.S., Bourgeat P., Ackermann U., Jones G., Szoeke C., Salvado O., Martins R., O'Keefe G., Mathis C.A., Klunk W.E., Ames D., Masters C.L., Rowe C.C. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann. Neurol. 2011, 69:181-192.
172. Vlassenko A.G., Vaishnavi S.N., Couture L., Sacco D., Shannon B.J., Mach R.H., Morris J.C., Raichle M.E., Mintun M.A. Spatial correlation between brain aerobic glycolysis and amyloid-beta (Abeta) deposition. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:17763-17767.
173. Wang H.X., Karp A., Winblad B., Fratiglioni L. Late-life engagement in social and leisure activities is associated with a decreased risk of dementia: a longitudinal study from the Kungsholmen project. Am. J. Epidemiol. 2002, 155:1081-1087.
174. Wiley C.A., Lopresti B.J., Venneti S., Price J., Klunk W.E., DeKosky S.T., Mathis C.A. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch. Neurol. 2009, 66:60-67.
175. Willis S.L., Tennstedt S.L., Marsiske M., Ball K., Elias J., Koepke K.M., Morris J.N., Rebok G.W., Unverzagt F.W., Stoddard A.M., Wright E. Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA 2006, 296:2805-2814.
176. Wishart H.A., Saykin A.J., McAllister T.W., Rabin L.A., McDonald B.C., Flashman L.A., Roth R.M., Mamourian A.C., Tsongalis G.J., Rhodes C.H. Regional brain atrophy in cognitively intact adults with a single APOE ε4 allele. Neurology 2006, 67:1221-1224.
177. Wolk D.A., Price J.C., Saxton J.A., Snitz B.E., James J.A., Lopez O.L., Aizenstein H.J., Cohen A.D., Weissfeld L.A., Mathis C.A., Klunk W.E., Dekoskym S.T. Amyloid imaging in mild cognitive impairment subtypes. Ann. Neurol. 2009, 65:557-568.
178. Yoshita M., Fletcher E., Harvey D., Ortega M., Martinez O., Mungas D.M., Reed B.R., DeCarli C.S. Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology 2006, 67:2192-2198.
179. Zandi P.P., Anthony J.C., Khachaturian A.S., Stone S.V., Gustafson D., Tschanz J.T., Norton M.C., Welsh-Bohmer K.A., Breitner J.C. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch. Neurol. 2004, 61:82-88.
180. Zhang Y., Schuff N., Jahng G.H., Bayne W., Mori S., Schad L., Mueller S., Du A.T., Kramer J.H., Yaffe K., Chui H., Jagust W.J., Miller B.L., Weiner M.W. Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology 2007, 68:13-19.